https://www.selleckchem.com/products/img-7289.html
The development of pulmonary fibrosis from sarcoidosis often causes major morbidity and mortality and should be a major focus of concern.Introduction Immune checkpoint inhibitor therapy and BRAF-targeted therapy have been developed for the treatment of metastatic melanoma. The optimal use of these agents, either in sequence or combination, for the 40-50% of melanoma patients whose tumors harbor a BRAFV600 mutation is unknown, but data from a number of clinical trials, including one randomized Phase II study, are emerging.Areas covered
Like
Comment
Share
